-
Posted by
Two Blokes Apr 21 -
Filed in
Stock
-
3 views
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, with a risk-adjusted U.S. revenue potential of $216 million annually.
